[go: up one dir, main page]

HK1041693B - 二聚化合物及作為神經氨酸的抑制劑 - Google Patents

二聚化合物及作為神經氨酸的抑制劑 Download PDF

Info

Publication number
HK1041693B
HK1041693B HK02103316.9A HK02103316A HK1041693B HK 1041693 B HK1041693 B HK 1041693B HK 02103316 A HK02103316 A HK 02103316A HK 1041693 B HK1041693 B HK 1041693B
Authority
HK
Hong Kong
Prior art keywords
group
compound
compound according
compounds
atoms
Prior art date
Application number
HK02103316.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1041693A1 (zh
Inventor
Wu Wen-Yang
Jin Betty
Original Assignee
Biota Scientific Management Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scientific Management Pty. Ltd. filed Critical Biota Scientific Management Pty. Ltd.
Publication of HK1041693A1 publication Critical patent/HK1041693A1/zh
Publication of HK1041693B publication Critical patent/HK1041693B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK02103316.9A 1999-03-12 2000-03-09 二聚化合物及作為神經氨酸的抑制劑 HK1041693B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP9139A AUPP913999A0 (en) 1999-03-12 1999-03-12 Novel chemical compounds and their use
AUPP913999 1999-03-12
PCT/AU2000/000165 WO2000055149A1 (en) 1999-03-12 2000-03-09 Dimeric compounds and as inhibitors of neuraminidase

Publications (2)

Publication Number Publication Date
HK1041693A1 HK1041693A1 (zh) 2002-07-19
HK1041693B true HK1041693B (zh) 2005-10-14

Family

ID=3813338

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103316.9A HK1041693B (zh) 1999-03-12 2000-03-09 二聚化合物及作為神經氨酸的抑制劑

Country Status (26)

Country Link
US (1) US6548476B1 (zh)
EP (1) EP1165541B1 (zh)
JP (1) JP5160000B2 (zh)
KR (1) KR100805906B1 (zh)
CN (1) CN1343205A (zh)
AP (1) AP2001002277A0 (zh)
AT (1) ATE295361T1 (zh)
AU (2) AUPP913999A0 (zh)
BR (1) BR0008939A (zh)
CA (1) CA2367755C (zh)
CZ (1) CZ20013274A3 (zh)
DE (1) DE60020100T2 (zh)
EA (1) EA200100968A1 (zh)
ES (1) ES2241581T3 (zh)
HK (1) HK1041693B (zh)
HU (1) HUP0200190A3 (zh)
ID (1) ID29868A (zh)
IL (1) IL145346A (zh)
MX (1) MXPA01009203A (zh)
NO (1) NO327812B1 (zh)
NZ (1) NZ514041A (zh)
PL (1) PL350228A1 (zh)
TR (1) TR200102794T2 (zh)
TW (1) TWI268279B (zh)
WO (1) WO2000055149A1 (zh)
ZA (1) ZA200107450B (zh)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9904009A3 (en) * 1996-11-14 2001-07-30 Biota Scient Man Pty Ltd Melbo Method and novel compounds for use therein
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
AUPR001000A0 (en) * 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AU2002340635B2 (en) * 2001-11-09 2008-03-13 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AUPR879501A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AU2002336823B2 (en) * 2001-11-09 2008-03-20 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
EP1451182B1 (en) 2001-11-09 2008-06-11 Biota Scientific Management Pty. Ltd. Dimeric compounds and their use as anti-viral agents
AU2002340632B2 (en) * 2001-11-09 2008-03-20 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AUPR879601A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879401A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
CN104383554B (zh) 2002-09-06 2018-06-08 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
US7144450B2 (en) * 2004-12-04 2006-12-05 Xerox Corporation Phase change inks containing trans-1,2-cyclohexane bis(urea-urethane) compounds
US7220300B2 (en) 2004-12-04 2007-05-22 Xerox Corporation Phase change inks containing bis(urea-urethane) compounds
US7153349B2 (en) 2004-12-04 2006-12-26 Xerox Corporation Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds
US7560587B2 (en) * 2004-12-04 2009-07-14 Xerox Corporation Bis[urea-urethane] compounds
US7317122B2 (en) 2004-12-04 2008-01-08 Xerox Corporation Curable trans-1,2-cyclohexane bis(urea-urethane) compounds
US7576235B2 (en) 2004-12-04 2009-08-18 Xerox Corporation Processes for preparing bis(urea-urethane) compounds
US7314949B2 (en) 2004-12-04 2008-01-01 Xerox Corporation Trans-1,2-cyclohexane bis(urea-urethane) compounds
US8227425B2 (en) * 2007-01-23 2012-07-24 Therapicon Srl Antiviral compounds
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2009006613A1 (en) * 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
WO2009006620A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
JP5597130B2 (ja) * 2007-07-03 2014-10-01 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸脱ｎ−アセチラーゼの阻害剤及びその使用方法
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
CA2774015A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
NL2005389A (en) 2009-10-21 2011-04-26 Asml Netherlands Bv Lithographic apparatus, device manufacturing method, and method of applying a pattern to a substrate.
IT1396620B1 (it) * 2009-11-25 2012-12-14 Therapicon Srl Analoghi chimerici
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
BR112013004275A2 (pt) * 2010-08-24 2016-08-02 Imp Innovations Ltd glicodendrímeros de polipropileterimina
HK1200106A1 (zh) * 2012-01-05 2015-07-31 阿拉维制药公司 扎那米韋生物利用度增强的製劑
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015184008A1 (en) 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3377487B1 (en) * 2015-11-20 2022-01-12 AusVir Therapeutics Pty Ltd Compounds for medicinal applications
RU2612221C1 (ru) * 2015-12-16 2017-03-03 Общество с ограниченной ответственностью "Синтавр" Блокаторы вируса гриппа
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
CN108003065B (zh) * 2016-10-27 2021-01-08 中国石油化工股份有限公司 一种具有增稠作用的化合物和润滑脂以及它们的制备方法
WO2018199798A1 (ru) * 2017-04-28 2018-11-01 Общество с ограниченной ответственностью "Синтавр" Пептидные производные противовирусного препарата занамивира
AU2018273411B2 (en) * 2017-05-25 2022-12-01 The Governors Of The University Of Alberta Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
CN111698999A (zh) * 2017-12-06 2020-09-22 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph为7的可注射溶液
CN113194983B (zh) * 2018-09-06 2025-11-18 奇达拉治疗公司 用于治疗病毒感染的组合物及方法
KR20210072015A (ko) * 2018-10-05 2021-06-16 에모리 유니버시티 단량체 및 다량체 항-hbv 제제
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013079A1 (en) * 1990-02-27 1991-09-05 Drug Delivery System Institute, Ltd. Derivative of glycolipid containing sialic acid
ATE193551T1 (de) * 1991-03-18 2000-06-15 Scripps Research Inst Oligosaccharide als enzymsubstrate und - inhibitoren: verfahren und zusammensetzungen
EP0638085A1 (en) * 1992-02-19 1995-02-15 The Biomembrane Institute Inhibition of cell adhesion by chemically-defined oligosaccharides, their derivatives, mimetics, and antibodies directed thereto
JPH0638784A (ja) * 1992-03-30 1994-02-15 Meiji Milk Prod Co Ltd シアル酸を構成要素とする糖鎖の製造方法
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
ATE305453T1 (de) * 1995-02-27 2005-10-15 Gilead Sciences Inc Selektive inhibitoren viraler oder bakterieller neuraminidase
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
HU223099B1 (hu) 1996-03-01 2004-03-29 Biota Scientific Managemant Pty. Ltd. Eljárás influenzavírus kimutatására és az eljárásban alkalmazható vegyületek
US5891862A (en) * 1996-03-15 1999-04-06 Geltex Pharmaceuticals, Inc. Polyvalent polymers for the treatment of rotavirus infection
AUPO104396A0 (en) 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
CA2261877C (en) * 1996-07-23 2009-04-07 Seikagaku Corporation Novel lactosamine oligosaccharide and method for producing the same
HUP9904009A3 (en) 1996-11-14 2001-07-30 Biota Scient Man Pty Ltd Melbo Method and novel compounds for use therein
JPH10182686A (ja) * 1996-12-26 1998-07-07 Ngk Insulators Ltd ガングリオシドＧＱ１ｂ類縁物質
JP3304985B2 (ja) 1997-04-17 2002-07-22 ジョンソン・エンド・ジョンソン株式会社 ケミカルインジケーターシートおよびそれを使用した滅菌用包装袋
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein

Also Published As

Publication number Publication date
EP1165541A4 (en) 2002-06-05
PL350228A1 (en) 2002-11-18
TR200102794T2 (tr) 2002-09-23
CA2367755C (en) 2007-08-28
IL145346A (en) 2005-11-20
EP1165541A1 (en) 2002-01-02
AP2001002277A0 (en) 2001-09-30
HUP0200190A2 (en) 2002-06-29
AU774222B2 (en) 2004-06-17
CZ20013274A3 (cs) 2002-03-13
MXPA01009203A (es) 2002-08-20
NO327812B1 (no) 2009-09-28
AUPP913999A0 (en) 1999-04-01
EP1165541B1 (en) 2005-05-11
US6548476B1 (en) 2003-04-15
NO20014409L (no) 2001-11-01
WO2000055149A1 (en) 2000-09-21
KR100805906B1 (ko) 2008-02-21
DE60020100T2 (de) 2006-01-19
NZ514041A (en) 2001-09-28
ATE295361T1 (de) 2005-05-15
DE60020100D1 (de) 2005-06-16
ID29868A (id) 2001-10-18
HUP0200190A3 (en) 2004-01-28
BR0008939A (pt) 2001-12-18
IL145346A0 (en) 2002-06-30
KR20020005617A (ko) 2002-01-17
JP5160000B2 (ja) 2013-03-13
EA200100968A1 (ru) 2002-02-28
NO20014409D0 (no) 2001-09-11
TWI268279B (en) 2006-12-11
CA2367755A1 (en) 2000-09-21
ES2241581T3 (es) 2005-11-01
JP2002539204A (ja) 2002-11-19
AU2896600A (en) 2000-10-04
ZA200107450B (en) 2002-09-10
CN1343205A (zh) 2002-04-03
HK1041693A1 (zh) 2002-07-19

Similar Documents

Publication Publication Date Title
EP1165541B1 (en) Dimeric compounds and as inhibitors of neuraminidase
CA2291994C (en) Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents
EP0848712B1 (en) Dihydropyran derivatives as viral neuraminidase inhibitors
WO1995020583A1 (en) Derivatives of 2-deoxy-2,3-dehydro-n-acetylneuraminic acid (dana)
EP0539204A1 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid
JP2010285436A (ja) 二量体化合物および抗ウイルス薬としてのそれらの使用
JP2010270130A (ja) 二量体化合物および抗ウイルス薬としてのそれらの使用
JP5179546B2 (ja) 二量体化合物および抗ウイルス薬としてのそれらの使用
KR101002794B1 (ko) 이량체 화합물 및 항바이러스제로서의 그의 용도
JP3923081B6 (ja) ウイルスノイラミニダーゼ阻害剤としてのジヒドロピラン誘導体
HK1015137B (zh) αD-神经氨(糖)酸的抗病毒4-取代-2-脱氧-2，3-二脱氢衍生物
HK1068344B (zh) 二聚化合物及其作为抗病毒剂的用途

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150309